Literature DB >> 17611911

Low-grade dysplasia in Barrett's esophagus has a high risk of progression.

C H Lim1, D Treanor, M F Dixon, A T R Axon.   

Abstract

BACKGROUND AND STUDY AIMS: Surveillance in Barrett's esophagus relies on the detection of dysplasia by histopathology. However, the natural history of this condition, particularly that of low-grade dysplasia (LGD) is poorly understood. This paper describes our experience of LGD over a period of 21 years. PATIENTS AND METHODS: Between 1984 and January 1995, 357 patients with Barrett's esophagus without dysplasia were recruited for annual surveillance: 34 of these patients developed LGD during this period. This was a retrospective cohort study of this group in terms of survival and cancer outcomes >/= 8 years after the original diagnosis of LGD, comparing them with the patients who did not develop LGD over the same period, with a histopathological review of the original diagnoses of LGD. The outcomes of 356/357 (99.7 %) of the patients were established in December 2004.
RESULTS: After 8 years, high-grade dysplasia (HGD) or cancer had developed in 9/34 patients with LGD (27 %) and in 16/322 controls (5 %). Cox's proportional hazards model revealed that the time from the first diagnosis of Barrett's esophagus to the first "event" of either HGD, esophageal cancer, or death did not show a statistically significant difference between the two groups. A further analysis treating death as "loss to follow-up" showed a significantly increased risk for the LGD group to progress to HGD or cancer (hazard ratio 5.9 [95 % confidence interval 2.6 - 13.4], P< 0.001). The histopathology review demonstrated a fair level of agreement between pathologists, with a kappa value of 0.48.
CONCLUSIONS: Patients diagnosed with LGD during surveillance of Barrett's esophagus are at a considerably increased risk of progressing to develop esophageal cancer over an 8-year period but most deaths are not cancer-related.

Entities:  

Mesh:

Year:  2007        PMID: 17611911     DOI: 10.1055/s-2007-966592

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  28 in total

1.  Barrett's Esophagus: A Review of Biology and Therapeutic Approaches.

Authors:  Panteleimon Kountourakis; Jaffer A Ajani; Marta Davila; Jeffrey H Lee; Manoop S Bhutani; Julie G Izzo
Journal:  Gastrointest Cancer Res       Date:  2012-03

2.  The cost effectiveness of radiofrequency ablation for Barrett's esophagus.

Authors:  Chin Hur; Sung Eun Choi; Joel H Rubenstein; Chung Yin Kong; Norman S Nishioka; Dawn T Provenzale; John M Inadomi
Journal:  Gastroenterology       Date:  2012-05-21       Impact factor: 22.682

Review 3.  Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis.

Authors:  Kavel Visrodia; Siddharth Singh; Rajesh Krishnamoorthi; David A Ahlquist; Kenneth K Wang; Prasad G Iyer; David A Katzka
Journal:  Gastroenterology       Date:  2015-11-24       Impact factor: 22.682

Review 4.  Screening and surveillance of Barrett's esophagus.

Authors:  Jeff Michalak; Ajay Bansal; Prateek Sharma
Journal:  Curr Gastroenterol Rep       Date:  2009-06

5.  Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.

Authors:  Shivaram Bhat; Helen G Coleman; Fouad Yousef; Brian T Johnston; Damian T McManus; Anna T Gavin; Liam J Murray
Journal:  J Natl Cancer Inst       Date:  2011-06-16       Impact factor: 13.506

Review 6.  Recent developments in pathogenesis, diagnosis and therapy of Barrett's esophagus.

Authors:  Magnus Halland; David Katzka; Prasad G Iyer
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

Review 7.  Disease Progression in Barrett's Low-Grade Dysplasia With Radiofrequency Ablation Compared With Surveillance: Systematic Review and Meta-Analysis.

Authors:  Bashar J Qumseya; Sachin Wani; Sherif Gendy; Ben Harnke; Jacques J Bergman; Herbert Wolfsen
Journal:  Am J Gastroenterol       Date:  2017-04-04       Impact factor: 10.864

8.  Carbonic anhydrases II, IX, and XII in Barrett's esophagus and adenocarcinoma.

Authors:  Minna Nortunen; Heikki Huhta; Olli Helminen; Seppo Parkkila; Joonas H Kauppila; Tuomo J Karttunen; Juha Saarnio
Journal:  Virchows Arch       Date:  2018-07-31       Impact factor: 4.064

Review 9.  Endoscopic risk factors for neoplastic progression in patients with Barrett's oesophagus.

Authors:  Angela Bureo Gonzalez; Jacques Jghm Bergman; Roos E Pouw
Journal:  United European Gastroenterol J       Date:  2016-03-02       Impact factor: 4.623

10.  Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia.

Authors:  Aaron J Small; James L Araujo; Cadman L Leggett; Aaron H Mendelson; Anant Agarwalla; Julian A Abrams; Charles J Lightdale; Timothy C Wang; Prasad G Iyer; Kenneth K Wang; Anil K Rustgi; Gregory G Ginsberg; Kimberly A Forde; Phyllis A Gimotty; James D Lewis; Gary W Falk; Meenakshi Bewtra
Journal:  Gastroenterology       Date:  2015-04-24       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.